BGPT: Paper Review: Advancements of CRISPR/Cas9 technology and its value in antiviral therapeutics

Explore by Goal

Quick Explanation Copied

What the paper does: A narrative review that frames CRISPR/Cas9 as an adaptable antiviral platform, covering core mechanism, sgRNA/Cas9 advantages, delivery formats, and key safety challenges (notably off-target activity and immunogenicity) using examples across multiple viruses.

Key mechanism claims align with foundational CRISPR/Cas9 studies (e.g., programmable RNA-guided cleavage and PAM-dependent targeting).

Long Explanation

Paper Review (Narrative Review): CRISPR/Cas9 and Antiviral Therapeutics

DOI: 10.62310/liab.v1i1.60 • Published: 2021-09-26 (as provided in the full text)

Stated scope

Mechanism, advantages vs older genome-editing nucleases, antiviral/vaccine applications, delivery approaches, and challenges.

Critical lens

Because this is a review (not a single primary study), the biggest scientific risk is overgeneralization from heterogeneous models and unequal evidence strength across viruses, cell systems, and delivery platforms.

VISUAL 1 — Key CRISPR/Cas9 milestones (timeline)

Evidence note: The review’s framing draws on core CRISPR observations and programmable Cas9 demonstrations, e.g., initial CRISPR locus reporting and Cas9 programmable cleavage . (If you want, I can tighten every timeline annotation to its exact DOI from the review’s reference list; the provided excerpt contains many DOIs but not all referenced items’ DOIs are present in your pasted bibliography.)

1) What is known vs what is asserted

Mechanism (well-supported):

CRISPR/Cas9 is an RNA-programmable DNA nuclease system where guide RNAs direct Cas9 cleavage at sequence-matched targets in a context that depends on PAM availability, with repair via NHEJ or HDR (conceptual mechanism alignment with canonical CRISPR/Cas9 literature).
The review also correctly notes that CRISPR can be used for functional disruption and multiplexing via multiple guides.

Antiviral therapeutic value (heterogeneous evidence):

The review compiles multiple virus examples (HIV, herpesviruses, HBV, HPV, SARS-CoV-2 via Cas13, etc.). For primary-study examples that the pasted full text explicitly supports:

HIV provirus / LTR targeting: CRISPR/Cas9 can induce mutations in HIV-1 LTR regions in cells, with the general rationale of disabling proviral transcription/activation.
Herpesviruses: The review cites examples where herpesvirus gene targeting restricts replication in vitro.
HBV cccDNA: The review claims CRISPR/Cas9 can target HBV cccDNA as a reservoir; a key example in the reference list is CRISPR targeting of HBV cccDNA.

Skeptical read: This kind of cross-virus compilation is useful for mapping feasibility, but it does not equal clinical-grade efficacy evidence. In particular, many cited antiviral results are in vitro or in limited model systems; the review itself acknowledges delivery and off-target risks as central barriers.

2) Delivery approaches: strengths & hidden assumptions

The review organizes delivery formats into viral (adenovirus, lentivirus, AAV) and non-viral (plasmid, mRNA, RNP; plus nanoparticles/electroporation and other mechanical approaches). This is consistent with the broad delivery challenge literature for CRISPR therapeutics.

Key blind spots created by narrative reviews:

Translation gap: Demonstrations in cell lines often cannot predict pharmacokinetics, biodistribution, tissue penetration, or long-term persistence of editing machinery.
Immunogenicity ≠ one number: Cas9 immunogenicity and vector immunogenicity can differ by dosing schedule and the delivery payload (protein vs mRNA vs AAV). The review notes immunogenicity as a major issue, consistent with broader literature on Cas9-directed immunity.
Vector-specific risk: Integrating viral vectors introduce their own risks independent of Cas9 off-target cutting (e.g., insertional mutagenesis risk is a known theme in integrating delivery). The review discusses lentiviral integration risk at a conceptual level; translating that into quantitative risk requires primary trial data, which a narrative review cannot supply.

3) Off-target effects & safety: what the review gets right—and what it cannot

Off-target editing and unintended genome damage are central safety questions. The review cites evidence that CRISPR/Cas9 can have substantial off-target activity in certain contexts and that mismatch tolerance depends on guide and system design.

Substantial off-target editing can occur: CRISPR/Cas9 targeting β-globin and CCR5 has been reported to have substantial off-target activity.
Strategies exist to reduce off-targets: The review discusses approaches such as paired nickases and truncated guide RNAs. Truncated guides have been shown to improve specificity in mammalian contexts.
RNP delivery can reduce persistent exposure: Direct RNP delivery reduces nuclease persistence, which is often expected to reduce off-target editing compared with sustained expression systems (conceptual safety rationale; the review cites studies supporting lower off-target signals with RNP approaches).

Critical limitation: The review cannot provide the distribution of off-target outcomes across tissues, dosing schedules, and patient genotypes. To be falsifiable at clinical scale, you need primary data from well-controlled studies using genome-wide off-target detection assays and long-term follow-up—rarely available uniformly across all viruses.

4) Evidence-quality mapping (what’s most credible)

Because the paper is a narrative review, the best “science action” is to classify evidence types.

Evidence-type distribution (qualitative, derived from the paper’s emphasis)

Important skepticism: This plot is a review-structure proxy, not a measured dataset. The review itself does not provide a numeric breakdown of evidence strength.

So treat this visualization as a reader heuristic, not as a factual quantitative claim.

5) Concrete recommendations to improve a future version (scientific, evidence-driven)

Separate “platform feasibility” from “therapeutic efficacy”: explicitly grade evidence (cell line vs primary cells vs animal vs clinical biomarkers) per virus.
Add falsification criteria: for each cited antiviral claim, state what would disconfirm it (e.g., lack of viral-load reduction, escape via indels, collateral toxicity signals, inability to reach relevant tissues).
Standardize off-target assessment references: map which genome-wide assay each example used (and its detection sensitivity limits), since off-target rates are assay-dependent.
Clarify which CRISPR mode is used: Cas9 (DNA) vs Cas13 (RNA) vs engineered variants; the review mentions both Cas9 and Cas13, so a reader needs an explicit table “virus → nuclease type → target → evidence model type.”

Author deep dives (link out)

Open the authors’ BGPT author reviews for targeted follow-ups.

Feedback:

Updated: April 06, 2026